Application and progress of PSMA-PET imaging in prostate cancer clinical trials
Prostate cancer is a common malignancy in the male urinary tract worldwide and one of the fastest growing male malignancies. Prostate-specific membrane antigen (PSMA) has emerged as an attractive diagnostic and therapeutic target for small molecule ligands in prostate cancer. Radiolabeled ligands can be used as imaging markers using positron emission tomography (PET) to confirm target expression in cancer, such as 68 Ga-PSMA-11 and 18 F-DCFPyL. The same ligands can also be labeled with therapeutic radionuclides for use in targeted radionuclide therapy, such as 177 Lu-PSMA-617. This combined approach allows for concomitant diagnostics to identify patients who may benefit from specific targeted therapies.PSMA-PET imaging, with its high sensitivity and specificity, will play an even greater role in the diagnosis and staging of prostate cancer patients, the detection of disease recurrence, and the assessment of efficacy. Based on Calyx’s experience, we will share and discuss the application scenarios, evaluation criteria, common challenges and regulatory considerations of PSMA-PET imaging in prostate cancer clinical trials.
时间
2023 年 10 月 17 日
8PM-9PM Beijing Time
发言人
Yibin Shao
Medical Director, Calyx MI
Currently leading the Medical Sciences Department at Calyx China, Yibin has extensive clinical trial and medical imaging experience, has supported over 100 BICR services for registration filing trials. She is a senior expert in the implementation and standardization of evaluation standards such as RECIST, iRECIST, IWG, Lugano, PCWG, mRECIST, RANO, etc.
